ATW1H%ASUACAD.BITNET@oac.ucla.edu (Dr David Dodell) (08/28/89)
--- begin part 2 of 2 cut here --- developing lung cancer, while women in the same category had seven times the risk. Study participants included 332 lung cancer patients and 865 controls from the island of Oahu. In order to ascertain the frequency and quantity of vegetable consumption, researchers administered dietary questionnaires to all subjects, and then classified the food groups on the basis of micronutrient content. Among vitamin A components, only consumption of beta-carotene and the other carotenoids with vitamin A activity was linked to cancer risk; beta- carotene showed a protective role. Its protective mechanism was strongest for male smokers, particularly for current and recent ex-smokers, whereas for women, only ex-smokers and those who had never smoked showed this protective effect. Of note, however, the researchers found that the reduction of lung cancer risk is greater for overall vegetable consumption than with beta- carotene intake per se. In addition, they reported that ``the study provides indirect evidence for a protective effect against lung cancer from the consumption of lycopene, lutein, and the cancer inhibitors particularly abundant in cruciferous vegetables.'' JOURNAL OF THE NATIONAL OF THE NATIONAL CANCER INSTITUTE August 2,1989;81:1158-64. (Compiled from Newspapers and Medical Journals for IMTS's Healthweek In Review.) Health InfoCom Network News Page 10 Volume 2, Number 31 August 28, 1989 =============================================================================== News from the National Institute of Dental Research =============================================================================== Dental News from the National Institute of Dental Research 07/13/89 CONSENSUS CONFERENCE URGES DENTAL TREATMENT FOR CANCER PATIENTS Among the one million Americans who are diagnosed with cancer each year, some 400,000 will develop oral complications from their cancer treatments. These painful and debilitating oral side effects, often severe enough to interfere with a patient's trex8mnt and recovery, were the subject of a National Institutes of Health Consensus Development Conference held April 17-19 on "The Oral Complications of Cancer Therapies: Diagnosis, Prevention, and Treatment." Copies of the Consensus Statement may be obtained by writing to the Public Inquiries and Reports Section, Office of Planning, Evaluation, and Communications, NIDR, NIH, Building 31, Room 2C35, 9000 Rockville Pike, Bethesda, MD 20892. Proceedings from the conference will be published later this year as a monograph of the Journal of the National Cancer Institute. RESEARCHERS LINK HPV TO ORAL AND PHARYNGEAL CANCER Using a sensitive genetic probe, University of North Carolina researchers recently found DNA traces from several human papillomaviruses (HPVs)--common causes of warts--in squamous cell carcinoma samples taken from patients with oral and pharyngeal cancer. This finding suggests that HPV's may play a role in the development of squamous cell carcinomas in this part of the body. Health InfoCom Network News Page 11 Volume 2, Number 31 August 28, 1989 =============================================================================== Food & Drug Administration News =============================================================================== Food Labelling Changes P89-36 Food and Drug Administration FOR IMMEDIATE RELEASE Jeff Nesbit - (301) 443-4177 July 28, l989 (Home) -- (703) 273-l043 HHS Secretary Louis W. Sullivan, M.D., today said that he has asked the Food and Drug Administration to consider "sweeping changes" in the way foods should be labeled. In August, as part of the initiative, FDA Commissioner Frank E. Young, M.D., Ph.D., will be publishing an advanced notice of proposed rule making describing this effort in detail. The FDA will also hold a series of three or four public hearings across the country beginning this fall to find out what consumers want and need on food labels. Under the guidelines set out by Dr. Sullivan, the FDA is expected to propose a federal rule on the various aspects of food labeling early next year. The FDA has long required certain labeling -- such as ingredients and net weight on packaged foods -- and has regulations for how nutritional information should be displayed. However, there is currently no comprehensive, mandatory food labeling requirement for nutritional labeling for all foods, despite the federal government's efforts to improve food labeling over the past two decades. "Interest in food labeling has never been higher," said Dr. Sullivan. "Food labeling bills have been introduced in Congress. Consumers are watching what they eat more closely. Scientific knowledge about the effects of diet on health has increased in recent years. And food manufacturers are providing more information to consumers on their food labels." Dr. Sullivan said the FDA will look at five major areas of food labeling during the public hearings this fall and as the agency begins the process of drafting the proposed federal rule, including: * NUTRITION LABELING Nutrition labeling is the voluntary listing of a food's nutritional value, including vitamins and minerals, calories, sodium, fat, protein and carbohydrates. Since the current list of elements was developed, there have been requests by both consumers and manufacturers to revise that list (e.g., to eliminate some of the items such as certain detailed vitamin information, and add others, such as cholesterol, fiber and saturated vs. unsaturated fat). According to surveys, consumers say that labeling food for its nutritional value is second in importance only to a listing of a food's ingredients. "For this reason, consumers might prefer to see the nutrition label extended from its present 55 percent of packaged foods," said Dr. Young. * LABEL FORMAT Health InfoCom Network News Page 12 Volume 2, Number 31 August 28, 1989 Just as nutrition information is sought by consumers, there is an increasing demand for more salient information in an easy-to-understand and useful fashion. Consumers want labels that help them to more readily identify foods as low in fat and cholesterol, high in fiber and low in sodium. The FDA will attempt to determine which label format is most helpful to consumers without imposing significant new regulatory burdens on industry. * INGREDIENT LABELING FDA regulations currently require packaged food labels to list their ingredients in descending order of predominance by weight (with bread, for example, labeled as containing flour, eggs, sugar, yeast, preservatives and artificial flavors and colors). The FDA will examine a number of proposals, including those that major ingredients should be listed by percentage, not just in order of weight; that minor ingredients be exempted from the order of predominance labeling; and that specific oil content be listed. * DESCRIPTIONS OF FOOD There are a number of ways in which the food label is used to describe foods -- names established by standards of identity, common or usual names, imitation of substitute foods, and descriptor labeling such as "low calorie," "low fat," "high fiber," "natural" and "organic." Other names for common foods have been invented to make them sound more attractive (such as "snow cod" for dogfish). The FDA will examine whether the use of these terms is useful or misleading, whether these terms in combination with other larger changes such as revised ingredient and labeling are necessary, and whether some should be standardized or prohibited, as well as whether some food standards should be revised to provide for improved nutritional characteristics or replaced by a simple, full listing of ingredients. * HEALTH MESSAGES ON FOOD LABELS In recent years, there has been increased use of food labels to impart health messages to consumers on everything from fiber's protective benefits against cancer and low cholesterol foods' effect on heart disease to high calcium foods' impact on osteoporosis. The FDA has traditionally determined that foods may not make such health- related claims. However, scientific evidence has accumulated to support at least some claims linking good diet to good health. To date, the FDA has not reached a regulatory position allowing such claims when they are appropriate while still protecting the public against fraudulent or misleading claims. FDA plans to reach a position on health messages on food labels with this initiative. This initiative will involve close cooperation with the Institute of Medicine which is under contract with the Public Health Service to review food labeling issues. In recent years, the Surgeon General's Report on Nutrition and Health and the National Academy of Science's Report on Diet and Health provided the nation with authoritative views on the evidence linking diet and nutrition to health. "I believe all parties will welcome this initiative," said Dr. Young. "Consumers want an opportunity to make the food label more useful. Health Health InfoCom Network News Page 13 Volume 2, Number 31 August 28, 1989 professionals believe that better information about nutrition will have benefits to health. And food manufacturers want to eliminate unnecessary food labeling requirements, yet be permitted to make greater use of the food label in conveying information about their products." ### Tuesday July 26, 1989 Surfactant P89-35 FOOD AND DRUG ADMINISTRATION FOR IMMEDIATE RELEASE Eva Kemper -- (301) 443-3285 July 26, 1989 Home -- (301) 972-9273 The Food and Drug Administration today authorized wide use of an experimental drug for the inside of the lungs to save thousands of premature infants born with a breathing difficulty called Respiratory Distress Syndrome. The syndrome is caused when the immature lungs of a premature infant are not yet producing a naturally occurring surfactant -- a foamy substance that coats the inside of the lungs and keeps them from collapsing when the infant exhales. FDA Commissioner Frank E. Young, M.D., Ph.D, announced that the FDA is making the drug, a synthetic surfactant, available on a wide basis through qualified hospitals to treat or prevent Respiratory Distress Syndrome. The syndrome is also called hyaline membrane disease. In 1963, a baby boy born to then-President and Mrs. John F. Kennedy died of the condition. Although in the past two decades great strides have been made against the syndrome, it remains a leading cause of death and disability among premature infants. Among about 250,000 infants born prematurely each year in the United States, up to 50,000 have the condition, which kills about 5,000. FDA Commissioner Young said, "When there is adequate evidence that a drug is effective and safe for a serious or life-threatening disease, and when no satisfactory alternative exists, we can make the drug available under a treatment IND -- before its approval for marketing -- with the cooperation of the manufacturer. In this case, Burroughs Wellcome Co. agreed to make the drug available early because of its potential benefit to thousands of infants throughout the U.S. It is important to note that the evidence has come from completed or partially completed controlled trials." Under the "treatment IND" (or investigational new drug application), the surfactant can be administered as a single dose immediately after birth to help prevent death in high-risk middle-sized premature infants (700-1,100 grams, or 1.5 to 2.5 pounds) or as two doses, 12 hours apart, to treat middle sized infants -- babies (700 - 1,350 grams, or 1.5 to 3 pounds) or large babies (more than 1,350 grams, or 3 pounds) who have the syndrome. The drug comes as a powder to be mixed with sterile water and then given through a tube into the lungs. The premature infants must be on a mechanical ventilator to receive the drug. The drug has been associated with an increase in episodes of apnea (temporary cessation of breathing). Under the Treatment IND protocols, Burroughs Wellcome Co. will make surfactant available to U.S. hospitals or institutions that can provide state- of-the-art perinatal care to high-risk mothers and infants. Burroughs Wellcome Co. of Research Triangle Park, N.C., will provide surfactant under the trade name Exosurf Pediatric. Exosurf was invented by Health InfoCom Network News Page 14 Volume 2, Number 31 August 28, 1989 Dr. John Clements of the University of California at San Francisco and licensed to Burroughs Wellcome Co. Physicians participating in the trials will receive the product at no cost. Physicians who have questions about the Treatment IND protocols can call Burroughs Wellcome Co. at 1-800-326-3282. ##### Nutrex Aminex P89-34 Food and Drug Administration FOR IMMEDIATE RELEASE Bill Grigg - (301) 443-3285 July 21, 1989 (Home) -- (202) 652-1864 The Food and Drug Administration warned hospitals nationally today not to use a nutritional powder called Nutrex Aminex made by the Nutrex Corporation of Sunnyvale, Calif., because it contains a potentially fatal amount of potassium. The powder is blended with water and administered by mouth or by gastric tube to patients unable to eat ordinary meals. The problem was discovered after a patient at the Veterans Administration Medical Center in Nashville, Tenn., developed heart arrhythmias and was discovered to have high blood potassium. The patient recovered when the administration of Aminex was withdrawn. Too much potassium can be fatal. VA and FDA tests subsequently showed the Aminex diet powder used to make the food was extremely high in the nutrient. FDA has not been successful in obtaining a list of institutions to which the product was sold, and thus issued a general press release in an attempt to get its warning to all hospitals. Packets of the powder, which are flavored strawberry, vanilla or orange and are unflavored, are labeled, "Nutritionally complete elemental diet for oral or tube feeding -- Nutrex Aminex Nutritional Powder." #### Tuesday July 18, 1989 Aids treatment Registry P89-33 Food and Drug Administration FOR IMMEDIATE RELEASE Brad Stone - (301) 443-3285 July 18, 1989 (Home) -- (703) 440-6042 HHS Secretary Louis W. Sullivan, M.D., today announced the completion of computerized listings through which AIDS patients and their doctors can get up-to-date information on clinical trials of AIDS drugs and vaccines -- whether federally or privately sponsored -- and the general criteria for participating in them. "The AIDS Clinical Trial Information Service is on-line and ready to provide the public with basic information concerning clinical trials," Secretary Sullivan said. "The data bank will provide the answers to important basic questions and tell individuals where to get further details." The listings were completed by a new data base developed by the Food and Drug Administration on clinical trials sponsored by private companies and Health InfoCom Network News Page 15 Volume 2, Number 31 August 28, 1989 organizations. This information complements that on federally sponsored trials furnished by the National Institute of Allergy and Infectious Diseases. Both are accessible via a Public Health Service toll-free hotline at 1-800 TRIALS-A. The Centers for Disease Control will administer the operation of this hotline as part of its AIDS Information Clearinghouse. The Public Health Service AIDS Clinical Trials Information Service was designed to provide greater access to information about the trials underway to test the efficacy of proposed treatments for AIDS and related conditions. The Public Health Service AIDS Clinical Information Service was mandated by the Health Omnibus Programs Extension Act passed by Congress in November 1988. The legislation also exempted basic information about clinical efficacy trials for AIDS-related treatments from federal laws which had barred FDA from disclosing any information on clinical trials without the sponsor's permission. FDA Commissioner Frank E. Young, M.D., Ph.D., said, "It is important that people obtain early information on efficacy trials, which a change in the law now permits us to provide. The information will enable people with AIDS to identify clinical trials more quickly and efficiently, and participate in them more widely." The FDA data base, which began operation today, contains information on every experimental AIDS and AIDS-related treatment undergoing clinical testing for efficacy in FDA-sanctioned trials. The information will include the name of the drug being tested, the indication for which the treatment is being tested, eligibility criteria for patient enrollment and the location of the clinical trial sites. In addition, FDA has requested each clinical trial sponsor to allow the release of information beyond that required by the law, including information about other experimental drugs that are in earlier, pre- efficacy stages of testing. FDA's recently established AIDS coordination staff developed this data base, working with other parts of the agency and with the pharmaceutical industry. #### Health InfoCom Network News Page 16 Volume 2, Number 31 August 28, 1989 =============================================================================== Meeting Announcements =============================================================================== SPECIAL ANNOUNCEMENT -------------------- MEDINFO 89 SINGAPORE 6TH WORLD CONGRESS OF MEDICAL INFORMATICS RAFFLES CITY CONVENTION CENTER 10-14 DECEMBER 1989 SINGAPORE INFORMATICS IN SUPPORT OF GLOBAL HEALTH ---------------------------------------------------------------- MESSAGE FROM DR K C LUN CHAIRMAN, SINGAPORE ORGANISING COMMITTEE MEDINFO 89 SINGAPORE DEAR FRIENDS OF IMIA, DUE TO UNFORESEEN CIRCUMSTANCES, THE IMIA BOARD AND THE MEDINFO 89 STEERING COMMITTEE HAD TO REVISE PLANS FOR MEDINFO 89, ORIGINALLY SCHEDULED TO BE HELD IN BEIJING, PEOPLE'S REPUBLIC OF CHINA FROM 16-20 OCTOBER 1989. THERE WILL NOW BE TWO MEDINFO 89: PART I IN BEIJING, AS SCHEDULED, AND PART II IN SINGAPORE. MEDINFO 89 SINGAPORE WILL BE HELD IN SINGAPORE FROM 10-14 DECEMBER 1989. ENTRUSTED WITH THIS HEAVY RESPONSIBILITY OF ENSURING THE SUCCESS OF THIS IMPORTANT INTERNATIONAL MEETING OF HEALTH INFORMATICIANS, THE SINGAPORE ORGANISING COMMITTEE HAS BEEN WORKING VERY HARD TO PREPARE FOR THE EVENT. YOU CAN CERTAINLY TELL BY THE SPEED IN WHICH WE HAD THE NEW DATES AND THE CONVENTION FACILITIES FIXED UP AND THIS PRELIMINARY ANNOUNCEMENT REACHING OUT TO YOU TO INFORM YOU OF THE CHANGE. I WISH TO GIVE YOU THE ASSURANCE THAT THERE WILL BE NO LET UP IN THE ENTHUSIASM OF MY OC IN ENSURING THAT YOU WILL HAVE A FIRST CLASS MEETING HERE IN DECEMBER IN A WORLD CLASS CONVENTION CENTRE, THE RAFFLES CITY CONVENTION CENTRE THAT HAS PAR EXCELLENCE CONVENTION, HOTEL AND SHOPPING FACILITIES. PLEASE NOTE THAT WE HAVE ALSO BEEN ABLE TO NEGOTIATE FOR YOU VERY COMPETITIVE ROOM RATES FOR A COMFORTABLE STAY AT THE WESTIN PLAZA AND WESTIN STAMFORD HOTELS, THE OFFICIAL CONVENTION HOTELS LOCATED WITHIN THE RAFFLES CITY. YOU WILL EXPERIENCE THE FULL SCIENTIFIC PROGRAM AT MEDINFO 89 SINGAPORE. PAPERS TO BE PRESENTED WILL MAINTAIN THE HIGH SCIENTIFIC STANDARD THAT HAS CHARACTERISED ALL PREVIOUS MEDINFOS. IN ADDITION TO THE SCIENTIFIC SESSIONS, WE WILL MAINTAIN THE EXHIBITION, DEMONSTRATIONS, WORKSHOPS, "MEET THE EXPERT" SESSIONS, VIDEO PRESENTATIONS, SOFTWARE EXCHANGE, AND POSTER SESSIONS. WE HAVE ALSO PLANNED FOR YOU A RICH VARIETY OF SOCIAL PROGRAMS. FOR THOSE OF YOU WHO ARE UNABLE TO TRAVEL TO CHINA, WE SHALL BE BRINGING A HISTORICAL PART OF CHINA TO YOU AT MEDINFO 89 SINGAPORE. OUR CONGRESS OPENING RECEPTION WILL BE A DINNER PARTY CUM EXHIBITION AT THE "EMPRESS", SINGAPORE'S LATEST MUSEUM THAT HOUSES A MASSIVE EXHIBITION OF AUTHENTIC IMPERIAL TREASURES FROM THE QING Health InfoCom Network News Page 17 Volume 2, Number 31 August 28, 1989 DYNASTY. THIS EXHIBITION IS MADE POSSIBLE THROUGH A HIGH LEVEL AGREEMENT BETWEEN THE GOVERNMENTS OF THE PEOPLE'S REPUBLIC OF CHINA AND SINGAPORE. WE HAVE ALSO ARRANGED POST-CONGRESS TOURS FOR YOU TO SPEND YOUR WINTER AT SOME OF THE TOP TOURISM SPOTS IN THE TROPICAL FAR EAST. WE SHALL BE ANNOUNCING THE DETAILS VERY SOON. YOU HAVE UNDOUBTEDLY SEEN IN THE MEDIA OR HEARD FROM YOUR FRIENDS HOW BEAUTIFUL AND CLEAN SINGAPORE IS AS AN ISLAND CITY AND HOW EFFICIENT AND MODERNISED SINGAPORE IS AS A CONVENTION CITY. HERE'S YOUR CHANCE TO VISIT SINGAPORE, THE TROPICAL GARDEN CITY. COME TO MEDINFO 89 SINGAPORE. WE LOOK FORWARD TO BEING YOUR HOST. CONGRESS VENUE -------------- ALL SESSIONS WILL TAKE PLACE AT THE RAFFLES CITY CONVENTION CENTRE, LOCATED ON LEVEL 4 OF THE WESTIN STAMFORD AND WESTIN PLAZA HOTELS. THE OPENING CEREMONY WILL TAKE PLACE ON SUNDAY, 10 DECEMBER AND THE SCIENTIFIC SESSIONS WILL BE HELD FROM 11 DECEMBER TO 14 DECEMBER 1989. SCIENTIFIC PROGRAMME -------------------- THE SCIENTIFIC PROGRAMME WILL CONSIST OF PLENARY SESSIONS, WITH INVITED SPEAKERS AND SUBMITTED PAPERS. THERE WILL ALSO BE WORKSHOPS, FREE COMMUNICATIONS, "MEET-THE-EXPERTS" SESSIONS, POSTER DISPLAYS AND SCIENTIFIC DEMONSTRATIONS. SCIENTIFIC TRADE EXHIBITION --------------------------- IN ORDER TO GIVE CONGRESS PARTICIPANTS AN OPPORTUNITY TO ACQUAINT THEMSELVES WITH THE LATEST DEVELOPMENTS IN HEALTH INFORMATICS HARDWARE AND SOFTWARE, A TRADE EXHIBITION WILL BE HELD WITHIN THE CONGRESS VENUE. COMPANIES INTERESTED IN PARTICIPATING IN THE TRADE EXHIBITION ARE ADVISED TO CONTACT THE ORGANISING COMMITTEE AS SOON AS POSSIBLE. SOCIAL PROGRAMME ---------------- AN ATTRACTIVE SOCIAL PROGRAMME WILL BE ARRANGED FOR PARTICIPANTS AND ACCOMPANYING PERSONS. THE MAIN ATTRACTION WILL BE A DINNER PARTY CUM EXHIBITION AT THE "EMPRESS" WHICH HOUSES A VAST COLLECTION OF AUTHENTIC IMPERIAL TREASURES FROM THE QING DYNASTY IN CHINA. OFFICIAL LANGUAGE ----------------- THE OFFICIAL LANGUAGE OF MEDINFO 89 SINGAPORE WILL BE ENGLISH. Health InfoCom Network News Page 18 Volume 2, Number 31 August 28, 1989 OFFICIAL TRAVEL AGENT --------------------- WORLD EXPRESS HAS BEEN APPOINTED AS THE OFFICIAL TRAVEL AGENT. THIS ORGANISATION, WITH ITS WORLDWIDE NETWORK OF OFFICES, WILL ASSIST IN ALL TRAVEL AND HOTEL ARRANGEMENTS. THEIR ADDRESS IS: WORLD EXPRESS PTE LTD 114 MIDDLE ROAD #05-01 SINGAPORE 0718 TEL: (65)-336-3877 TLX: (65)-33372 FAX: (65)-339-8625 ATTN: MEDINFO 89 SINGAPORE REGISTRATION ------------ REGISTRATION FEES (US$) ARE AS FOLLOWS: BEFORE OCT 1 ON/AFTER OCT 1 ACTIVE PARTICIPANTS US$320 US$360 STUDENT PARTICIPANTS US$100 US$120 ACCOMPANYING PERSONS US$115 US$129 EXHIBITION PARTICIPANTS US$ 50 US$ 50 TRAVEL AND VISAS ---------------- A VALID INTERNATIONAL PASSPORT IS NECESSARY. FREE 14-DAY ENTRY VISA WILL BE GRANTED UPON ARRIVAL AT CHANGI INTERNATIONAL AIRPORT FOR SOCIAL VISITS TO ALL EXCEPT NATIONALS OF THE FOLLOWING COUNTRIES: AFGHANISTAN, CAMBODIA, LAOS, PEOPLE'S REPUBLIC OF CHINA, SOVIET UNION AND VIETNAM. FOR THESE NATIONALS, VISA APPLICATIONS SHOULD BE MADE IN ADVANCE FROM THE NEAREST SINGAPORE DIPLOMATIC MISSION. PARTICIPANTS TRAVELLING ON A HONG KONG DOCUMENT OF IDENTITY OR A HOLDER OF A REFUGEE TRAVEL DOCUMENT ISSUED BY THE ARAB COUNTRIES WILL ALSO REQUIRE ADVANCE VISA APPLICATION. PARTICIPANTS ARE NEVERTHELESS ADVISED TO CHECK WITH THEIR MINISTRY OF FOREIGN AFFAIRS OR THE NEAREST SINGAPORE DIPLOMATIC MISSION. INTERNATIONAL HEALTH CERTIFICATES ARE REQUIRED FOR ARRIVALS FROM YELLOW FEVER ENDEMIC/INFECTED AREAS. HOTEL RESERVATION ----------------- THE OFFICIAL CONGRESS HOTELS ARE THE WESTIN PLAZA AND THE WESTIN STAMFORD. Health InfoCom Network News Page 19 Volume 2, Number 31 August 28, 1989 THE OC HAS RESERVED ROOMS AT SPECIAL CONGRESS ROOM RATES OF US$80++ FOR THE PLAZA AND US$70++ FOR THE STAMFORD. ROOMS WILL BE AVAILABLE ON A FIRST-COME- FIRST-SERVED BASIS. A ONE-NIGHT ROOM DEPOSIT IS NECESSARY TO CONFIRM HOTEL BOOKING. TO ENJOY THESE CONCESSION RATES, HOTEL BOOKINGS MUST BE MADE EITHER THROUGH THE OC SECRETARIAT OR THE OFFICIAL TRAVEL AGENT, WORLD EXPRESS PTE LTD. NOTE: A ONE-NIGHT ROOM DEPOSIT PAYABLE TO "MEDINFO 89 SINGAPORE" IS REQUIRED TO CONFIRM HOTEL RESERVATION. ( ++ REFERS TO 10% SERVICE CHARGE AND 3% GOVT.TAX) THE UNIT OF CURRENCY FOR SINGAPORE IS THE SINGAPORE DOLLAR. (US$1.00 = APPROX S$2.00) FOR FURTHER INFORMATION CONCERNING REGISTRATION, HOTEL RESERVATIONS, EXHIBITIONS, PLEASE CONTACT: THE SECRETARIAT MEDINFO 89 SINGAPORE C/O DEPT OF COMMUNITY, OCCUPATIONAL AND FAMILY MEDICINE NATIONAL UNIVERSITY HOSPITAL LOWER KENT RIDGE ROAD SINGAPORE 0511 TEL: (65)-772-4299 FAX: (65)-772-4252 BITNET: LUNKC @ NUSVM TELEX: UNISPO RS33943 TELEGRAM: UNIVSPORE ********************************************************************* ********************************************************************* * * * THIS SPECIAL ANNOUNCEMENT HAS BEEN ISSUED FOR THE INFORMATION * * OF THE MANY PEOPLE WHO HAVE ENQUIRED ABOUT "MEDINFO 89 SINGAPORE" * * IT PRECEDES A COLOURFUL "SPECIAL ANNOUNCEMENT" FLYER WHICH IS * * CURRENTLY BEING PRINTED AND WILL BE DISTRIBUTED SHORTLY. * * * ********************************************************************* ********************************************************************* Health InfoCom Network News Page 20 --- end part 2 of 2 cut here ---